HealthEquity, Inc. (HQY) VP Jon Soldan Sells 25,000 Shares of Stock
HealthEquity, Inc. (NASDAQ:HQY) VP Jon Soldan sold 25,000 shares of HealthEquity stock in a transaction dated Monday, August 28th. The stock was sold at an average price of $40.68, for a total value of $1,017,000.00. Following the transaction, the vice president now owns 30,652 shares in the company, valued at $1,246,923.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
HealthEquity, Inc. (NASDAQ:HQY) traded up 2.81% during mid-day trading on Thursday, hitting $42.78. The company had a trading volume of 248,881 shares. The firm has a market capitalization of $2.57 billion, a PE ratio of 80.41 and a beta of 1.73. The company’s 50 day moving average price is $46.96 and its 200-day moving average price is $45.88. HealthEquity, Inc. has a 12-month low of $30.34 and a 12-month high of $54.95.
HealthEquity (NASDAQ:HQY) last announced its quarterly earnings results on Tuesday, June 6th. The company reported $0.19 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.16 by $0.03. HealthEquity had a net margin of 17.04% and a return on equity of 11.61%. The business had revenue of $55.40 million for the quarter, compared to analysts’ expectations of $54.77 million. During the same quarter last year, the firm earned $0.15 EPS. The firm’s revenue for the quarter was up 25.9% compared to the same quarter last year. On average, analysts forecast that HealthEquity, Inc. will post $0.59 EPS for the current fiscal year.
WARNING: This report was posted by Watch List News and is the property of of Watch List News. If you are viewing this report on another website, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this report can be accessed at https://www.watchlistnews.com/healthequity-inc-hqy-vp-jon-soldan-sells-25000-shares-of-stock/1534624.html.
Several analysts have issued reports on the company. Oppenheimer Holdings, Inc. reissued an “outperform” rating and issued a $61.00 price target (up previously from $57.00) on shares of HealthEquity in a research note on Monday, June 12th. Zacks Investment Research raised HealthEquity from a “hold” rating to a “buy” rating and set a $54.00 price target on the stock in a research note on Wednesday, July 12th. Cantor Fitzgerald lifted their price target on HealthEquity from $55.00 to $56.00 and gave the company an “overweight” rating in a research note on Wednesday, July 5th. BidaskClub downgraded HealthEquity from a “buy” rating to a “hold” rating in a research note on Monday, July 24th. Finally, Chardan Capital lifted their price target on HealthEquity from $53.00 to $57.00 and gave the company a “buy” rating in a research note on Wednesday, June 7th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $50.22.
A number of institutional investors have recently made changes to their positions in the stock. Fifth Third Bancorp boosted its position in shares of HealthEquity by 382.8% in the first quarter. Fifth Third Bancorp now owns 2,414 shares of the company’s stock valued at $102,000 after buying an additional 1,914 shares during the last quarter. Oppenheimer Asset Management Inc. purchased a new stake in HealthEquity during the first quarter valued at approximately $106,000. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in HealthEquity by 105.8% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,544 shares of the company’s stock valued at $127,000 after buying an additional 1,308 shares during the period. Riverhead Capital Management LLC raised its stake in HealthEquity by 75.3% in the second quarter. Riverhead Capital Management LLC now owns 2,629 shares of the company’s stock valued at $131,000 after buying an additional 1,129 shares during the period. Finally, Exane Derivatives purchased a new stake in HealthEquity during the second quarter valued at approximately $132,000. 91.86% of the stock is currently owned by institutional investors and hedge funds.
HealthEquity Company Profile
HealthEquity, Inc provides a range of solutions for managing healthcare accounts (Health Savings Accounts (HSAs), Health Reimbursement Arrangements (HRAs) and Flexible Spending Accounts (FSAs)) for health plans, insurance companies and third-party administrators. The Company is engaged in technology-enabled services platforms that allow consumers to make healthcare saving and spending decisions.
Receive News & Ratings for HealthEquity Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HealthEquity Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.